<DOC>
	<DOCNO>NCT01985451</DOCNO>
	<brief_summary>In trial , treat relapse PCNSL temozolomide , pemetrexed . Our objective ass treatment strategy ' availability base response rate , progression-free survival ( PFS ) , median PFS , toxicity .</brief_summary>
	<brief_title>Pemetrexed Temozolomide Treating Patients With Relapsed Primary Central Nervous System Lymphoma （PCNSL）</brief_title>
	<detailed_description>The best report outcomes PCNSL treatment high-dose methotrexate-based chemotherapy combine whole-brain radiation therapy ( WBRT ) . Despite aggressive therapy , however , nearly 50 % patient relapse within 24 month diagnosis . Furthermore , application high-dose methotrexate-based regimen complex , need hydrate , alkalify detoxify , treatment-related toxicity mortality severe . In attempt improve upon poor result reduce treatment-related side effect , treat 15-20 relapsed PCNSL patient fail high-dose methotrexate-based chemotherapy . Our objective ass treatment strategy ' availability base response rate , progression-free survival ( PFS ) , median PFS , toxicity .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically confirm primary CNS lymphoma . ECOG ( Eastern Cooperative Oncology Group ) Performance status 01 . Positive cerebrospinal fluid ( CSF ) cytology immunohistochemical diagnosis CSF monoclonality without measurable intracranial disease . Measurable ( great 1 cm diameter ) tumor CT scan MRI . Progressed firstline chemotherapy and/or radiotherapy OR relapse initial successful treatment . No systemic lymphoma CT scan chest , abdomen , pelvis contrast . No leptomeningeal lymphoma lumbar puncture CNS cytology/flow cytometry . No ocular lymphoma slit lamp examination . Must adequate organ function define protocol : Adequate renal function : serum creatinine ≤ 1.5 mg/dl and/or calculate creatinine clearance ≥ 60 ml/min ; Adequate hepatic function : bilirubin level ≤ 1.5 x ULN , ASAT &amp; ALST ≤ 1.5 x ULN.Adequate bone marrow reserve : neutrophil ( ANC ) count ≥ 1500 /mm^3 , platelet count ≥ 100,000 /mm^3 , hemoglobin ≥ 9 g/dl . Age &gt; /= 18 &lt; /= 75 year . Signed write informed consent prior study entry . Patients human immunodeficiency virus seropositivity systemic lymphoma manifestation . Serious uncontrolled concurrent illness . Previous brain radiotherapy , systemic chemotherapy . Concurrent chronic systemic immune therapy , target therapy indicate study protocol . Any evidence prior exposure Hepatitis B virus . Unable comprehend study requirement likely comply study parameter . Pregnant ( confirm serum urine βHCG ) lactating .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Lymphoma</keyword>
</DOC>